+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an intervention to reduce non-communicable disease NCD risks among pregnant women attending routine antenatal care ANC in urban health centers across four Ethiopian cities. The study focuses on improving maternal health behaviors and pregnancy outcomes by addressing unhealthy diets, low physical activity, and air pollution exposure, factors linked to increased health risks for mothers and newborns and potential long-term NCD development. The trial compares two groups one receiving standard routine ANC and the other receiving structured lifestyle counseling integrated into ANC visits. This counseling targets diet, physical activity, and air pollution behaviors, supported by health worker training, facilitation by trained staff, and a digital ANC eRegistry for clinical decision support. The study is conducted in 77 urban health centers with about 1,268 pregnant women enrolled before 20 weeks gestation and followed through delivery. Participants attend routine ANC visits where data on birth weight and maternal behaviors are collected, alongside assessments of counseling quality and ANC service delivery. Additional biomarker studies analyze maternal and newborn samples for early NCD risk markers. Researchers monitor implementation feasibility and acceptability through surveys, routine data, and interviews. The total study duration covers pregnancy until delivery, with data collected at baseline, during pregnancy, and up to 18 months post-intervention for some measures.

Age: 18Years +FEMALEPhase Not Applicable
4 locations
A

Actively Recruiting

Researchers are evaluating whether taking azithromycin as a preventive treatment can reduce the risk of death in adults with advanced HIV disease. This is a Phase 3, double-blind, placebo-controlled trial involving multiple centers. The study aims to understand if azithromycin prophylaxis can lower mortality compared to a placebo in this vulnerable population. Participants will be randomly assigned to receive either an oral azithromycin tablet or a matching placebo tablet once daily for 28 days. After this treatment period, they will be followed for 24 weeks to measure the main outcome of all-cause mortality. The total study participation will last 48 weeks to monitor both short-term and longer-term effects. During the study, participants will undergo assessments to track survival and hospitalizations at 12 and 24 weeks after starting the treatment. Researchers will closely monitor health outcomes and any hospital stays to evaluate the impact of azithromycin prophylaxis. Safety and adherence will be followed throughout the trial to ensure accurate measurement of results.

Age: 18Years +All GendersPhase 3
52 locations